glp-1 drug liraglutide may protect against dementia brain from AD Cardiovascular Protection with a Long-Acting
Description
By both providing novel data and supporting previous work, our study demonstrates that allulose supplementation in a WD context can modulate body weight, food consumption, and metabolic parameters in a manner that favors improved metabolic health
Their paper, published in 2009, was the first to report weight loss effects of dual-agonist drugs
Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder
AD, Alzheimers disease
The identification of dysregulated incretin secretion and action in both obesity and diabetes led to the revolutionary discovery of incretin-based drugs, such as glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic peptide (GIP)/GLP-1 RAs [24,25,26,27,28]
